Revumenib (SNDX-5613)
Menin Inhibitor
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)
BEAT-AML
(ven/aza combination)
Frontline KMT2Ar and mNPM1 AML
INTERCEPT
(monotherapy)
MRD- progression in KMT2Ar and mNPM1 AML
Colorectal Cancer
(monotherapy)
Unresectable metastatic microsatellite stable CRC
Axatilimab (SNDX-6352)
CSF-1R mAB
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)
Entinostat (SNDX-275)
Class 1 HDAC Inhibitor
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)
Revumenib (SNDX-5613)
Menin Inhibitor
BEAT-AML
Frontline KMT2Ar and mNPM1 AML
Phase 1
INTERCEPT
MRD- progression in KMT2Ar and mNPM1 AML
Phase 1
Colorectal Cancer
Unresectable metastatic microsatellite stable CRC
Phase 1
Axatilimab (SNDX-6352)
CSF-1R mAB
Entinostat (SNDX-275)
Class 1 HDAC Inhibitor